Galactorrhea

Galactorrhea is milk production or secretion from the breast unrelated to pregnancy or breastfeeding — conventionally defined as discharge occurring at least a year after childbirth and the end of breastfeeding — that is typically bilateral, arises from multiple ducts, and is milky, though it can appear watery, yellow, green, or brown.^[1][2]

Unlike most anterior pituitary hormones, prolactin is under predominantly inhibitory hypothalamic control: hypothalamic dopamine is delivered through the hypophyseal portal circulation to the anterior pituitary, where it binds D2 receptors on lactotroph cells and tonically suppresses prolactin secretion. Anything that lowers hypothalamic dopamine synthesis or release, blocks the D2 receptor directly, or interrupts the pituitary stalk connecting the two structures disinhibits prolactin secretion and raises the circulating level — hyperprolactinemia — which in turn can drive galactorrhea.^[1][2]

In routine practice, drug-induced hyperprolactinemia is the single most commonly identified cause of pathologic galactorrhea, which makes a careful, comprehensive medication history the highest-value diagnostic step a pharmacist can contribute — and it is the organizing focus of this chapter. Beyond medications, the differential includes a prolactin-secreting pituitary adenoma (prolactinoma), primary hypothyroidism, chest wall irritation or trauma, renal failure, and idiopathic disease, all of which need to be actively screened for rather than assumed away once a plausible causative drug is found.^[1][3]

Pathophysiology — dopamine's inhibitory brake, and what removes it

Prolactin secretion is normally held in check by hypothalamic dopamine acting on D2 receptors on anterior pituitary lactotrophs. A second, independent stimulatory pathway exists: thyrotropin-releasing hormone (TRH) — released in higher amounts whenever reduced thyroid hormone negative feedback raises hypothalamic drive — binds TRH receptors on lactotrophs and directly stimulates prolactin secretion, which is the mechanism connecting primary hypothyroidism to hyperprolactinemia and galactorrhea.^[1] Estrogen independently stimulates lactotroph proliferation and prolactin gene transcription, which explains both the physiologic prolactin rise of pregnancy and why estrogen-containing medications can raise prolactin outside of pregnancy.^[3]

The pharmacist-critical drug-induced etiology list — organized by mechanism

A thorough medication history — prescription, over-the-counter, herbal/supplement, and recreational — is the single most useful step in this presentation. The list below is organized by mechanism, since understanding why a drug raises prolactin helps predict which alternative might avoid it.

• Dopamine-receptor-antagonist antipsychotics — first-generation (typical) antipsychotics (e.g., haloperidol, chlorpromazine, fluphenazine) produce potent, broad D2 blockade, including at the tuberoinfundibular pathway that governs prolactin, and carry a high risk across essentially the whole class.^[4][3] Among second-generation (atypical) antipsychotics, risk varies markedly by agent: risperidone and its active metabolite paliperidone are genuine outliers, producing prolactin elevation in a majority of treated patients and levels that can specifically exceed 200 mcg/L, a threshold few other agents reach.^[3][4] The mechanism is specific to these two agents — both are substrates for P-glycoprotein at the blood-brain barrier, which actively transports them out of brain tissue proper while sparing the anterior pituitary, a structure that sits outside the blood-brain barrier; the result is that pituitary D2 receptors see disproportionately high drug exposure even at doses producing only modest central antipsychotic D2 occupancy. By contrast, aripiprazole (a partial D2 agonist), clozapine, and quetiapine are consistently identified as carrying the lowest prolactin-elevating liability among second-generation agents, and are useful alternatives to discuss with a prescriber when a lower-liability option is clinically appropriate.^[4]
• GI dopamine-receptor antagonists — metoclopramide and domperidone, prescribed for nausea, gastroparesis, or reflux, cause galactorrhea through the identical D2-blockade mechanism and are a commonly overlooked cause precisely because they are not mentally filed alongside psychiatric drugs.^[1][3] Notably, this same pharmacology is deliberately exploited in a different clinical context: domperidone is used off-label, at low dose, specifically to increase milk supply in breastfeeding patients — see Special Populations.
• Antidepressants — SSRIs and TCAs are reported causes, plausibly through serotonergic pathways that inhibit hypothalamic dopaminergic tone, though the evidence quality and mechanistic certainty are weaker than for antipsychotics.^[3][1]
• Opioids — chronic opioid use lowers hypothalamic dopamine tone through mu-opioid-receptor-mediated suppression, raising prolactin (and, separately, causing hypogonadism through the same suppressed hypothalamic-pituitary axis).^[3][1]
• Verapamil — reported to inhibit hypothalamic dopamine release or synthesis by a mechanism that remains incompletely defined; notably, this appears specific to verapamil rather than a class effect shared by other calcium channel blockers.^[3][1]
• Estrogen-containing therapies — estrogen-containing oral contraceptives and menopausal hormone therapy can raise prolactin and trigger galactorrhea through direct lactotroph stimulation, independent of any dopaminergic mechanism.^[3]

Non-drug causes to screen for

• Prolactinoma (pituitary adenoma) — the key non-drug differential, classified as a microprolactinoma (under 10 mm) or macroprolactinoma (10 mm or larger); imaging is warranted when no drug cause is found, when a suspected causative drug cannot be stopped and prolactin remains elevated, or when prolactin is markedly elevated (see Assessment/Diagnosis and Red Flags for thresholds).^[5]
• Primary hypothyroidism — via the TRH-mediated mechanism above; a genuinely reversible endocrine cause that resolves as thyroid status is corrected.^[1]
• Chest wall stimulation or trauma — chronic nipple stimulation, breast surgery, burns, or herpes zoster involving the chest wall can trigger a neurogenic reflex arc that mimics the suckling stimulus and raises prolactin.^[1]
• Renal failure — reduced renal clearance of circulating prolactin, sometimes compounded by altered hypothalamic dopaminergic tone.^[1][3]
• Idiopathic — after a complete workup, some cases remain unexplained; a proportion of patients labeled idiopathic are later found, on extended follow-up, to have a microprolactinoma too small to have been visible on the original imaging.^[2]

• Female sex and reproductive age.
• Use of any causative medication above — particularly a first-generation antipsychotic or risperidone/paliperidone among second-generation agents, metoclopramide or domperidone, chronic opioid therapy, verapamil, or an estrogen-containing contraceptive or hormone therapy.
• Recent pregnancy or recent cessation of breastfeeding — prolactin can remain physiologically elevated for a period after weaning, which is why true (pathologic) galactorrhea is conventionally defined as discharge persisting at least a year after childbirth and the end of breastfeeding.^[1]
• Polycystic ovary syndrome — modestly elevated prolactin is found in a meaningful minority of women with PCOS.^[1]
• Primary hypothyroidism.
• Chronic kidney disease, including hemodialysis.
• Chest wall trauma or surgery (including breast augmentation or reduction), burns, herpes zoster, or habitual nipple stimulation or self-manipulation.
• A known or suspected pituitary or hypothalamic mass lesion.
• Acute physical or psychological stress, and vigorous exercise, both of which can transiently elevate prolactin — worth accounting for when timing a blood draw.^[1]

History

• Onset, laterality, and character of the discharge — bilateral, multiductal, and milky supports true galactorrhea; unilateral, single-duct, bloody, or associated with a mass points toward pathologic nipple discharge instead (see Red Flags).
• A comprehensive medication history — prescription, over-the-counter, herbal/supplement, and recreational — reviewing the causative list in Recognize the Condition. This is the genuine first-line diagnostic step, given how common drug-induced causes are in practice.
• Menstrual and fertility history; symptoms of hypothyroidism; visual symptoms or headache; known renal disease; chest wall trauma, surgery, or habitual nipple stimulation; the possibility of pregnancy.

Examination

• Breast examination to characterize the discharge as above, and to check for a palpable mass, skin change, or axillary lymphadenopathy.
• Visual field confrontation testing.
• Signs of hypothyroidism.

Investigations

• Serum prolactin — ideally drawn without recent nipple stimulation, breast examination, exercise, or significant acute stress in the preceding interval, all of which can transiently raise the level and confound interpretation.^[1]
• TSH — to identify or exclude primary hypothyroidism as a reversible cause.
• Pregnancy test — in any patient of reproductive age, since prolactin rises physiologically in pregnancy.
• Renal function (creatinine) if chronic kidney disease is suspected as a contributing cause.
• If a clear causative drug is identified and the prolactin level is consistent with that specific drug (see Red Flags for the thresholds worth pausing on), a trial of stopping or switching the agent — in coordination with the prescriber — followed by rechecking prolactin no earlier than about 3 days later (the time typically required for levels to normalize after an oral causative drug is discontinued) is a reasonable, guideline-supported next step before proceeding to imaging.^[3]
• The "hook effect" is an immunoassay artifact in which an extremely high prolactin level saturates the assay's detecting antibody and produces a falsely low reported result. Suspect this specifically when a large pituitary mass (over 3 cm) is found on imaging alongside a normal or only mildly elevated prolactin level, and request the laboratory perform a serial dilution of the sample to obtain an accurate result.^[1]
• Pituitary MRI with dedicated pituitary views and contrast is indicated when: no clear cause is found on history, examination, and the routine testing above; a suspected causative drug cannot be stopped or substituted and prolactin remains elevated; prolactin is markedly elevated (see Red Flags); or the patient has other pituitary-suggestive symptoms (visual field change, headache) or galactorrhea with amenorrhea.^[1][3] If prolactin is not actually elevated on testing, no further hormone testing or imaging is needed — a normal prolactin level essentially excludes a drug- or prolactinoma-driven cause and redirects the workup toward idiopathic or physiologic galactorrhea.^[1]

• Identify and, wherever clinically appropriate and in coordination with the prescriber, adjust the causative medication — this is the single highest-value pharmacist action, since most drug-induced galactorrhea is genuinely reversible.
• Normalize serum prolactin and resolve the galactorrhea itself, rather than treating the discharge symptomatically in isolation.
• Correct the specific underlying driver — a reversible medication, primary hypothyroidism, or a prolactinoma — rather than defaulting to empiric dopamine agonist therapy before the cause is established.
• Restore menstrual regularity and fertility where hyperprolactinemia-driven hypogonadism has suppressed them.
• Protect long-term bone health: chronic hyperprolactinemia-driven hypogonadism is linked to a clinically meaningful reduction in bone density that is not guaranteed to fully reverse once prolactin normalizes, so this needs to be treated as a genuine treatment goal, not an afterthought.^[3]
• Avoid missing a prolactinoma, primary hypothyroidism, or an underlying malignancy behind what looks at first glance like straightforward drug-induced galactorrhea.
• Coordinate any medication change with the prescriber rather than recommending unilateral discontinuation — especially for an antipsychotic controlling active psychiatric illness.
• Provide reassurance, and avoid unnecessary testing or anxiety, for genuinely physiologic or idiopathic, non-bothersome galactorrhea.

• Avoid repeated breast self-examination, expression, or nipple stimulation — this perpetuates the neurogenic/reflex component of prolactin secretion and delays resolution, and is worth stating explicitly for idiopathic and mild drug-induced cases alike.^[2]
• Reassurance and explicit education for physiologic, idiopathic, or expected and reversible drug-induced galactorrhea.
• Address a non-pharmacologic underlying driver directly where relevant — proper wound care for chest wall burns or herpes zoster, a well-fitting bra to reduce chronic nipple friction, or optimized dialysis adequacy in renal failure.
• Coordinate any medication change with the prescriber rather than recommending a unilateral stop, particularly for a psychiatrically necessary antipsychotic.
• Bone-health counseling (adequate calcium and vitamin D intake, weight-bearing activity) for a patient with a period of hyperprolactinemia-driven hypogonadism, given the real and not-always-reversible bone density loss this can cause.^[3]
• Psychosocial support — embarrassment, worry about an underlying cancer, or concern about fertility are all common and reasonable reactions; address them directly rather than only the biochemistry.
• Set a defined follow-up point after any medication change (prolactin recheck no earlier than about 3-4 days, with clinical reassessment at about 4 weeks), so a case that is not improving is identified and escalated rather than left open-ended.

Patients on antipsychotic therapy

Risk varies markedly by agent: first-generation antipsychotics and, among second-generation agents, risperidone and paliperidone carry the highest prolactin-elevating liability, while aripiprazole, clozapine, and quetiapine carry the lowest.^[4] When a change is warranted, switching to a lower-liability agent is reported to be more effective than simply reducing the dose of the same agent, particularly when amenorrhea is present.^[7] Adjunct aripiprazole — typically around 5 mg/day added to the existing antipsychotic — is a genuinely evidence-based strategy that normalizes prolactin in up to about 79% of patients within roughly 3 months, without requiring the primary antipsychotic to be stopped, and is a useful option to raise with the prescriber when the causative agent is otherwise working well psychiatrically.^[7] Dopamine agonists (cabergoline or bromocriptine) should be reserved for cases where aripiprazole augmentation is ineffective, and used only in coordination with psychiatry and endocrinology, given the risk of exacerbating the underlying psychiatric illness.^[7][3] Never recommend stopping or switching an antipsychotic unilaterally — always involve the psychiatric team.

Patients on GI dopamine antagonists

Metoclopramide and domperidone, prescribed for nausea, gastroparesis, or reflux, are a commonly overlooked cause since they are not mentally filed alongside psychiatric drugs; review the ongoing indication and consider whether a non-dopaminergic alternative or a time-limited course could apply. Note the deliberate paradox worth naming for patients and prescribers alike: domperidone is also used, off-label and at low dose, specifically to increase milk supply in breastfeeding patients who want more prolactin — the identical pharmacology that causes unwanted galactorrhea in a non-lactating patient is intentionally exploited in that different clinical context.

Pregnancy and fertility

A pregnancy test is a first-line investigation in any reproductive-age patient presenting with galactorrhea, since prolactin rises physiologically in pregnancy. For a patient with a known microprolactinoma who becomes pregnant, dopamine agonist therapy is typically discontinued once pregnancy is confirmed, since the risk of clinically significant tumor growth during pregnancy is low. For a larger tumor (a macroprolactinoma, particularly one over 3 cm), growth risk during pregnancy is higher, and continued treatment or closer monitoring — including periodic visual field testing — may be needed; this decision belongs with endocrinology.^[5]

Breastfeeding

Normal lactation is, by definition, not galactorrhea — expected milk production during breastfeeding is physiologic. Dopamine agonists suppress milk production and should be avoided, or used only with specific counseling, in a patient who wishes to continue breastfeeding.

Male patients

Galactorrhea in men is less often physiologic and carries a comparatively higher likelihood of an underlying prolactinoma; men who present with a prolactinoma are considerably more likely to have a macroadenoma than a microadenoma at diagnosis, likely reflecting delayed recognition since galactorrhea is a less obvious and less monitored symptom in men.^[5] Galactorrhea and gynecomastia frequently coexist in men given their shared hyperprolactinemia-driven mechanism — see the Gynecomastia chapter for a fuller discussion of the breast findings themselves.

Renal impairment

Chronic kidney disease, including hemodialysis, reduces prolactin clearance directly and is itself an independent cause, not only a modifier of a medication-induced picture — factor this in alongside any medication review rather than assuming a drug alone explains the finding.

Older adults

A greater polypharmacy burden increases the chance that more than one contributing drug is present at once — review the full medication list systematically rather than stopping at the first plausible culprit found.

• After a medication change for suspected drug-induced galactorrhea, confirm the change was actually made, then recheck prolactin no earlier than about 3 days later — the time typically required for levels to normalize after an oral causative agent is stopped — and reassess symptoms clinically at about 4 weeks.^[3]
• For dopamine agonist therapy targeting a prolactinoma: monitor prolactin periodically during titration (for example, monthly) and every 3-6 months once a stable, normalized level is reached; repeat pituitary MRI at about 3 months for a macroadenoma and periodically thereafter to confirm shrinkage; obtain formal visual field testing for any tumor close to the optic chiasm.
• For cabergoline doses above 2 mg/week, schedule echocardiography every 2-3 years given the associated risk of valvular heart disease at higher cumulative exposure.^[5]
• After 2 or more years of sustained normal prolactin with no visible tumor remnant on MRI, a supervised trial of dopamine agonist discontinuation is reasonable — but counsel explicitly that recurrence is genuinely common (reported in roughly a quarter to two-thirds of patients, most often within the first year off treatment), so a defined follow-up plan after stopping matters just as much as the decision to stop.^[3]
• Monitor menstrual regularity and fertility status as a marker of treatment success in a patient with hyperprolactinemia-driven hypogonadism.
• Consider bone density (DEXA) assessment in a patient with a prolonged period of hyperprolactinemia-driven hypogonadism, since bone loss is not guaranteed to fully reverse with prolactin normalization alone.^[3]
• Document the suspected or confirmed cause and the response to any change, especially for a patient on long-term antipsychotic therapy, where this may recur as a topic across visits.

1. No improvement in suspected drug-induced galactorrhea a reasonable interval (several weeks) after the causative agent was stopped or switched: recheck prolactin, reconsider whether another cause (thyroid, renal, prolactinoma) was missed, and pursue TSH, a repeat prolactin level, and imaging as indicated, rather than assuming the medication review simply failed.
2. No response, or intolerance, to cabergoline: switch to bromocriptine (or vice versa) before concluding the case is dopamine-agonist-resistant.
3. True resistance or intolerance to both dopamine agonists: refer for transsphenoidal surgical evaluation.^[5]
4. A growing macroadenoma, or a persistent or worsening visual field defect, despite adequate dopamine agonist dosing: refer urgently to neurosurgery rather than continuing to escalate the medical dose indefinitely.
5. Causative antipsychotic cannot be changed and galactorrhea remains bothersome: try aripiprazole augmentation before a dopamine agonist, and reserve a dopamine agonist for aripiprazole-refractory cases, used only in close coordination with psychiatry and endocrinology.^[7]
6. Recurrence after a supervised dopamine agonist discontinuation trial: resume therapy rather than repeating the withdrawal attempt shortly afterward, and reset the clock on the 2-year normoprolactinemia requirement before considering another attempt.^[3]
7. New or worsening red-flag findings at any point, even after a previously reassuring workup: treat as a new presentation and refer promptly, rather than assuming simple progression of a known benign cause.

• Ordering a pituitary MRI before completing the basic first-line workup (medication history, prolactin, TSH, pregnancy test) — imaging is a later step, not the first one, in the majority of cases.
• Treating every antipsychotic as an equal prolactin risk — missing that risperidone and paliperidone are genuine outliers among second-generation agents, or that aripiprazole, clozapine, and quetiapine are comparatively prolactin-sparing options worth discussing with the prescriber.
• Overlooking metoclopramide or domperidone as the cause because they are gastrointestinal, not psychiatric, drugs.
• Recommending a patient unilaterally stop or switch a psychiatrically necessary antipsychotic without involving the prescriber or psychiatric team.
• Starting a dopamine agonist in a patient on an antipsychotic without coordinating with psychiatry, given the real risk of exacerbating the underlying psychiatric illness.
• Missing a prolactin level that is disproportionately high relative to what the causative drug alone would be expected to produce, and failing to consider a coexisting prolactinoma.
• Confusing true galactorrhea (bilateral, multiductal, milky) with pathologic nipple discharge (unilateral, single-duct, bloody, or mass-associated) — the two need entirely different workups.
• Failing to request a diluted sample when a large pituitary mass is found alongside an unexpectedly modest prolactin level — the hook-effect scenario.
• Forgetting to recheck prolactin after correcting hypothyroidism, rather than assuming resolution without confirming it.
• Advising a patient with idiopathic or mild galactorrhea to regularly check for continued discharge by expressing the breast — this itself perpetuates the reflex and delays resolution.
• Ignoring the bone-health implications of a prolonged period of hyperprolactinemia-driven hypogonadism.

How to use this table: doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment and pregnancy status. Select any drug name to open its complete Pharmasist Drug Database page.

Dopamine Agonist Therapy — Prolactinoma or Persistent Hyperprolactinemia

Reserved for a confirmed prolactinoma, or for persistent, bothersome hyperprolactinemia with no reversible cause found. Use with extreme caution, and in coordination with the psychiatric team, in any patient on an antipsychotic, given the risk of exacerbating the underlying psychiatric illness.

Treating an Identified Underlying Cause

Not a treatment for galactorrhea directly — corrects the reversible driver, after which galactorrhea and hyperprolactinemia are expected to resolve on their own.